Cambium Oncology
An early-stage biotechnology company developing novel checkpoint inhibitors for a broad range of tumor types with traditionally poor prognoses.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
* | $2.4m | Grant | |
| Total Funding | 000k | ||
Related Content
Cambium Oncology is an early-stage biotechnology company focused on developing innovative checkpoint inhibitors to treat a wide range of tumors with traditionally poor prognosis. The company's proprietary molecules have shown efficacy in several critical mouse models of cancer, such as pancreatic cancer and acute myeloid leukemia. Cambium Oncology has discovered a novel role for the neuropeptide vasoactive intestinal peptide (VIP) in promoting cancer by antagonizing the action of dendritic cells and tumor-infiltrating T lymphocytes. This VIP signaling allows tumors to evade immune destruction. To counteract this, Cambium Oncology has developed an extensive library of VIP checkpoint inhibitor peptides aimed at restoring T cell tumor-killing activity. One of their lead antagonists, VIP ANT308, has demonstrated significant improvements in anti-tumor activity. The company primarily serves the oncology market, targeting healthcare providers and research institutions. Cambium Oncology operates on a business model that includes research and development, clinical trials, and potential partnerships or licensing agreements to generate revenue.
Keywords: biotechnology, checkpoint inhibitors, tumor, pancreatic cancer, acute myeloid leukemia, VIP, immune evasion, T cells, oncology, research.